7-Hydroxymitragynine vs Kratom

Your liver does the work — unless you skip the step

A kratom leaf contains 40+ alkaloids, dominated by mitragynine (~66% of total alkaloid content) with only trace 7-OH. When you ingest leaf, mitragynine is converted to 7-OH in vivo by CYP3A4 — and that conversion is the rate-limiting step for kratom’s opioid effect (Kruegel 2019). A concentrated 7-OH tablet skips that step. You are receiving the active opioid alkaloid directly, at a dose your liver did not have to manufacture from a much larger pool of parent compound.

The receptor profile is also narrower: 7-OH binds mu with roughly 13× the affinity of morphine and 46× that of mitragynine (Kruegel 2016), and rats generalise it to morphine in drug-discrimination assays while mitragynine is not generalised (Obeng 2021).

What the difference feels like

Low-dose kratom leaf — 2 to 4 grams — feels closer to strong coffee than to an opioid. Users describe sharpened focus, mild mood lift, physical energy, and a slight edge of sociability. This is the stimulant-like character of mitragynine before CYP3A4 has converted enough to 7-OH for the opioid effect to dominate. It’s the reason kratom is a Rubiaceae (coffee-family) plant, and the reason traditional Southeast Asian use was as a work-productivity aid, not a sedative.

A concentrated 7-OH product — even at the low end of the user-reported range (1–5 mg) — produces opioid-typical warmth, analgesia, relaxation, and euphoria from the start. There is no stimulant phase. The subjective profile sits closer to a low-dose pharmaceutical opioid than to kratom leaf, because you are receiving the same active alkaloid that the leaf eventually produces — just pre-formed, in larger quantities, faster.

The honest framing is not “which is stronger” but “how much 7-OH reaches the receptor, and how fast.” Concentrated 7-OH wins on both.

Why 7-OH costs more — and why that matters

Kratom leaf is cheap: $8–15 per 100 grams of powder, which lasts a regular user 20+ sessions. A 7-OH tablet runs $2–4 each, and tolerance escalation means daily users quickly move from one tablet to three, four, eight. At that cadence, a 7-OH habit can cost $200–500+ per month — a financial strain that rarely gets mentioned in product marketing. The cost asymmetry also makes switching back to leaf economically appealing but pharmacologically frustrating: users whose tolerance was set by concentrated 7-OH find leaf “doesn’t work” anymore.

Dependence builds on the same mechanism — just faster

Chronic kratom users develop a dose-dependent withdrawal syndrome paralleling opioid withdrawal (Singh 2014), and rats self-administer isolated 7-OH at rates comparable to morphine while ignoring isolated mitragynine (Hemby 2019). The clean read: leaf kratom carries opioid-like dependence risk that builds over months of regular use; concentrated 7-OH compresses that timeline because the rate-limiting conversion step is gone. Full mechanism and tapering framework on the withdrawal page.

The legal line between leaf and concentrate

A growing number of US states draw the legal line exactly where the pharmacology draws the risk line: at concentration. Variants of the Kratom Consumer Protection Act adopted across multiple states cap 7-OH at 1–2% of total alkaloids — a threshold that permits natural-leaf products while excluding the concentrated extract market. Specific examples:

• Oklahoma — caps 7-OH at 1% of total alkaloids. An August 2025 audit found 30 stores selling products at up to 92%, nearly 100× the legal limit.
• Kansas — Governor Kelly signed HB 2365 on April 10, 2026, placing all kratom (including leaf) on Schedule I effective July 1, 2026.
• Tennessee— Matthew Davenport’s Law passed both chambers and is awaiting the governor’s signature. If signed, possession becomes a Class A misdemeanor effective July 1, 2026.
• Colorado, Georgia, Minnesota — KCPA variants allowing leaf while banning synthetic or concentrated products.

Full per-state detail including statutes, effective dates, and enforcement posture on the state-by-state legal tracker.

If you’re considering switching

Switching from leaf to concentrated 7-OH is a dose escalation, not a lateral substitution. You are moving from a slow, liver-metered delivery of a few milligrams of 7-OH per session to a direct, unmetered delivery of 10–80 mg. Your tolerance will reset to the higher delivery rate within days. Going back to leaf afterward often fails — not because the leaf “stopped working” but because your receptor baseline moved.

If you’re new to both: start with leaf. If you’re already on leaf and considering 7-OH: read the dosage guide first, start at the absolute bottom of the beginner range (1–3 mg), and understand that you are beginning a relationship with a different pharmacological profile than what you know.